Comparative efficacy and safety of oral versus subcutaneous methotrexate in the treatment of psoriasis: a systematic review, pairwise and network meta-analysis with CINeMA and GRADE assessment
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-02039-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Nesreen Alhamwi und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, The University of Jordan, Amman, Jordan. nesreen.alhamwi@gmail.com. Hauptthemen laut MEDLINE: Methotrexate, Psoriasis, Dermatologic Agents. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Methotrexate (MTX) is a cornerstone of systemic therapy for treating moderate to severe psoriasis. It can be given orally or subcutaneously (SC). SC MTX offers higher bioavailability and more predictable exposure. However, head-to-head clinical evidence is limited. We systematically compared the efficacy and safety of SC and oral MTX to inform route selection. METHODS: Building upon this background, we conducted a systematic review and network meta-analysis with random effects. Randomized controlled trials (RCTs) were identified from major databases up to 2025. Ten RCTs met the inclusion criteria. Outcomes included change in Psoriasis Area and Severity Index (PASI) from baseline, PASI 50/75/90/100 responses, and adverse events. Treatments were ranked using the Surface Under the Cumulative Ranking curve (SUCRA) probabilities. RESULTS: Our review and analysis showed that, across analyses, subcutaneous methotrexate (SC MTX) ranked higher than oral methotrexate (oral MTX) for PASI75 (SUCRA 0.98 vs. 0.52), PASI90 (0.98 vs. 0.39), and PASI100 (0.93 vs. 0.50). Subcutaneous methotrexate increased the odds of PASI75 (OR 5.48, 95% CI 2.53-11.85) and PASI90 (OR 3.33, 95% CI 1.09-10.13). Oral methotrexate slightly favored PASI50. Neither formulation reached significance for PASI100. Mean PASI reduction did not differ directly, despite superior rankings for subcutaneous methotrexate. Subcutaneous methotrexate was also associated with fewer adverse events and lower rates of discontinuation. CONCLUSION: SC MTX more effectively achieves PASI thresholds and is better tolerated, supporting its use as the preferred systemic treatment for moderate to severe psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, The University of Jordan, Amman, Jordan. nesreen.alhamwi@gmail.com.
- School of Medicine, The University of Jordan, Amman, Jordan.
- School of Medicine, Al-Balqa' Applied University, As-Salt, Jordan.
- Ministry of Health, Amman, Jordan.
Zitieren
APA
Alhamwi, N., Saleh, A. O., Hammadeh, B. M., Aldeeb, O. M., Shawwa, A., Lafi, L., Elkadri, L., Mohsen, A., Mansour, N. J., Rizik, A., Al Halasa, Z., & Aljarrah, A. (2025). Comparative efficacy and safety of oral versus subcutaneous methotrexate in the treatment of psoriasis: a systematic review, pairwise and network meta-analysis with CINeMA and GRADE assessment. Inflammopharmacology. https://doi.org/10.1007/s10787-025-02039-8
Vancouver
Alhamwi N, Saleh AO, Hammadeh BM, Aldeeb OM, Shawwa A, Lafi L, et al. Comparative efficacy and safety of oral versus subcutaneous methotrexate in the treatment of psoriasis: a systematic review, pairwise and network meta-analysis with CINeMA and GRADE assessment. Inflammopharmacology. 2025. doi:10.1007/s10787-025-02039-8
BibTeX
@article{Alhamwi2025,
author = {Alhamwi, Nesreen and Saleh, Ahmad Omar and Hammadeh, Bara M and Aldeeb, Osama M and Shawwa, Abdallah and Lafi, Layan and Elkadri, Lina and Mohsen, Ayat and Mansour, Noor J and Rizik, Aseel and Al Halasa, Zeina and Aljarrah, Ammar},
title = {Comparative efficacy and safety of oral versus subcutaneous methotrexate in the treatment of psoriasis: a systematic review, pairwise and network meta-analysis with CINeMA and GRADE assessment},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-02039-8}
}
EUVIMED